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ABSTRACT
KRAS mutations are an established predictor of lack of response to EGFR-
targeted therapies in patients with metastatic colorectal cancer (mCRC). However, 
little is known about the role of the rarer NRAS mutations as a mechanism of primary 
resistance to the anti-EGFR monoclonal antibody cetuximab in wild-type KRAS mCRC. 
Using isogenic mCRC cells with a heterozygous knock-in of the NRAS activating 
mutation Q61K, we aimed to elucidate the mechanism(s) by which mutant NRAS 
blocks cetuximab from inhibiting mCRC growth. NRASQ61K/+ cells were refractory to 
cetuximab-induced growth inhibition. Pathway-oriented proteome profiling revealed 
that cetuximab-unresponsive ERK1/2 phosphorylation was the sole biomarker 
distinguishing cetuximab-refractory NRASQ61K/+ from cetuximab-sensitive NRAS+/+ 
cells. We therefore employed four representative MEK1/2 inhibitors (binimetinib, 
trametinib, selumetinib, and pimasertib) to evaluate the therapeutic value of MEK/
ERK signaling in cetuximab-refractory NRAS mutation-induced mCRC. Co-treatment 
with an ineffective dose of cetuximab augmented, up to more than 1,300-fold, the 
cytotoxic effects of pimasertib against NRASQ61K/+ cells. Simultaneous combination of 
MEK1/2 inhibitors with cetuximab resulted in extremely high and dose-dependent 
synthetic lethal effects, which were executed, at least in part, by exacerbated 
apoptotic cell death. Dynamic monitoring of real-time cell growth rates confirmed 
that cetuximab synergistically sensitized NRASQ61K/+ cells to MEK1/2 inhibition. Our 
discovery of a synthetic lethal interaction of cetuximab in combination with MEK1/2 
inhibition for the NRAS mutant subgroup of mCRC underscores the importance of 
therapeutic intervention both in the MEK-ERK and EGFR pathways to achieve maximal 
therapeutic efficacy against NRAS-mutant mCRC tumors.
INTRODUCTION
Mutations in KRAS (35-45%) are a well-established 
predictor for lack of response to EGFR-targeted therapies 
in patients with metastatic colorectal cancer (mCRC), and 
are examined routinely to identify those patients unlikely 
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to benefit from these therapies [1-4]. Recent studies have 
demonstrated that the evaluation of an extended panel 
of RAS mutations, including mutations in NRAS, can 
better define the patient population unlikely to benefit 
from anti-EGFR therapy while concomitantly improving 
the outcomes in a more highly selected RAS wild-type 
group [4-8]. However, although much is known about the 
prognostic and predictive roles of the highly prevalent 
KRAS mutations in mCRC, less is known about the role of 
the rarer NRAS mutations (3%) as a mechanism of primary 
resistance to EGFR-targeted therapies in KRAS wild-type 
mCRC. 
 Since they typically do not coexist in the same 
tumor [9-11], it is possible that mutations in KRAS and 
NRAS genes are functionally redundant as they could 
provide similar or identical oncogenic signals. However, 
recent molecular evidence supports the idea that mutations 
in KRAS and NRAS are not mutually exclusive; rather, 
they constitute molecular events that are specifically 
selected in response to significantly different tumorigenic 
contexts [12, 13]. In mice genetically engineered to 
express mutationally activated forms of KRAS and 
NRAS in the intestinal epithelium, mutant KRAS induces 
hyperproliferation of the colonic epithelium, which 
manifests as the appearance of a chronic intestinal 
hyperplasia [12]. Mutant KRAS therefore seems to 
enhance the transition from a benign adenoma to a 
malignant adenocarcinoma in a context of inactivation 
of the tumor suppressor gene adenomatous polyposis 
coli (APC). By contrast, mutant NRAS does not affect the 
initial homeostasis or tumor progression but inhibits the 
ability of intestinal epithelial cells to undergo programmed 
cell death in response to chronic exposure to apoptotic 
stimuli [13]. In this regard, it should be noted that both 
acute and chronic inflammation significantly contributes 
to colorectal cancer progression [14]. Accordingly, recent 
studies in genetically modified animals confirm that mutant 
NRAS might accelerate colorectal cancer development in 
the setting of inflammation [13]. At present, however, how 
and why the anti-apoptotic phenotype associated with 
activating mutations in NRAS can contribute to the origin, 
progression and response to targeted treatment of mCRC 
with anti-EGFR monoclonal antibodies such as cetuximab 
and panitumumab remains unknown.
NRAS is the least studied member of the RAS family 
of GTPases, and consequently the oncogenic properties 
associated with this isoform are not well characterized. 
Moreover, directly targeting oncogenic NRAS is extremely 
challenging for rational drug design, and no clinically 
available mechanism-based therapy for tumors with 
oncogenic NRAS mutations exists. We here envisioned 
that a careful characterization of the oncophenotype 
caused by the interaction of clinically relevant activating 
NRAS mutations with the phospho-proteome generated in 
response to EGFR-targeted therapies might facilitate the 
discovery of more effective therapies for the subgroup 
of patients with NRAS-mutated mCRC. We applied this 
approach to survey the changes in the phospho-proteome 
in an isogenic mCRC model (SW48 cells), in which one 
allele of the endogenous NRAS gene was edited to harbor 
an activating mutant c.181 C > A (Q61K). Using SW48 
NRASQ61K/+ cells, we herein describe a therapeutically 
targetable mechanism whereby mutant NRAS prevents 
cetuximab from inhibiting mCRC growth but is responsive 
to the development of an effective drug mix involving 
cetuximab and currently available MEK1/2 inhibitors. 
RESULTS
Heterozygous knock-in of the NRAS activating 
mutation Q61K is sufficient to promote loss of 
sensitivity to cetuximab in a model of mCRC
We utilized an SW48-based mCRC model to 
evaluate the impact of an activating NRAS mutation on 
the efficacy of the anti-EGFR monoclonal antibody 
cetuximab. To do this, we used SW48 colon cancer 
cell lines in which one allele of the endogenous NRAS 
gene contained a heterozygous knock-in of the c.181C 
> A activating mutation, resulting in an amino acid 
substitution from glutamine (Q) to lysine (K) at position 
61. As expected, NRASQ61K/+ cells were fully refractory to 
cetuximab-induced reduction in cell viability, whereas a 
strong reduction of cell viability was noted for parental 
NRAS+/+ cells in the presence of 100 µg/mL cetuximab 
(Figure 1). The isogenic introduction of the PIK3CA 
c.3140A > G (H1047R) activating mutation into NRAS+/+ 
cells, which results in an amino acid substitution at 
position 1047 in PIK3CA, from a histidine (H) to an 
arginine (R), failed to alter the sensitivity to cetuximab in 
SW48 mCRC cells (Figure 1). 
A low-scale proteomic analysis of NRAS-mutant 
mCRC cells reveals phosphorylation of MEK1/2 
as the most relevant biomarker of resistance to 
cetuximab
To examine whether the differential effects of 
cetuximab on EGFR-dependent cell survival were 
related to constitutive changes in signaling components 
downstream of EGFR, we comprehensively surveyed the 
phosphorylation status of multiple intracellular kinases in 
NRAS+/+ and NRASQ61K/+ cells in the absence or presence 
of cetuximab using low-scale semi-quantitative phospho-
proteomics. 
Using the commercially available Proteome Profiler 
Human Phospho-MAPK Array kit (24 MAPK-related 
kinases), we found that NRAS+/+ cells exhibited a strong 
constitutive activation of ERK2 (T185/y187) and ERK1 
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Figure 1: Mono-allelic activation of NRAS is sufficient to confer refractoriness to cetuximab in mCRC cells. Cell 
viability of NRAS+/+, NRASQ61K/+, and PIK3CAH1047R/+ SW48 cells cultured with 100 µg/mL cetuximab was assessed using an MTT assay. All 
assays were performed at least three times in triplicate. n. s. Non-significant differences were identified by Student´s t test for paired values; 
* P < 0.01 compared to control cells by Student´s t test for paired values.
Figure 2: ERK1/2 activation is unresponsive to cetuximab resistance in NRAS mutant mCRC cells. Left panels. Phospho-
proteome profiling of mCRC cells in response to cetuximab. Total cell lysates (750 µg) from NRAS+/+ and NRASQ61K/+ cells before and after 
treatment with 100 µg/mL cetuximab (48 h) were incubated on membranes of the phospho-proteomics platforms, human Phospho-MAPK 
(top panels; 23 different MAPKs and other serine/threonine kinases) and human Phospho-Kinase Arrays (bottom panels; 43 different 
kinases and 2 related total proteins), as described in “Methods and materials”. Figure shows representative phospho-proteome analyses. 
Equivalent results were obtained in two independent experiments. Right panels. Bar graphs show the results of densitometry analysis of the 
scanned phospho-arrays. Signal values include the background correction and the intensities normalization to the corresponding positive 
control values on each array. 
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(T202/Y204), which was markedly reduced in response to 
cetuximab treatment (Figure 2, top panels). By contrast, 
the constitutive activation of ERK2 and ERK1 remained 
largely unchanged in cetuximab-treated NRASQ61K/+ cells 
(Figure 2, top panels). Thus, in the presence of cetuximab, 
cetuximab-refractory NRASQ61K/+ cells exhibited an 
approximately 3-fold up-regulation in ERK1/ERK2 
activity when compared to cetuximab-sensitive NRAS+/+ 
parental cells (Figure 2, top panels). Although less 
pronounced, the activation status of p70 S6 kinase (T421/
S424) followed a pattern similar to that for ERK1/ERK2, 
i.e., whereas cetuximab treatment markedly reduced 
p70S6K activity in cetuximab-sensitive NRAS+/+ cells, 
phospho-active p70S6K was less responsive to cetuximab 
treatment in NRASQ61K/+ cells (Figure 2, top panels). 
Using the Human Phospho-Kinase Array, which 
is capable of simultaneously detecting the relative 
phosphorylation levels of 43 kinases and 2 related 
proteins, we confirmed that cetuximab-unresponsive 
ERK1/2 phosphorylation was the sole biomarker that 
distinguished cetuximab-refractory NRASQ61K/+ from 
cetuximab-sensitive NRAS+/+ parental cells (Figure 2, 
bottom panels). Additionally, cetuximab treatment reduced 
the activation status of with no lysine kinase (WNK), a 
negative regulator of the activation of MEK/ERK [15, 
16], in cetuximab-refractory NRASQ61K/+ cells but not in 
Figure 3: NRAS mutant mCRC cells are more resistant to MEK1/2 inhibitors. Cell viability of NRAS+/+, NRASQ61K/+, and 
PIK3CAH1047R/+ cells cultured with the MEK1/2 inhibitors binimetinib, trametinib, selumetinib, and pimasertib was assessed using an MTT 
assay. Concentrations causing 50% reduction in cell viability (IC50 values) were calculated in the absence (top) or presence (bottom) of 
cetuximab. * P < 0.01 compared with control cells by ANOVA followed by Scheffé’s multiple contrasts. 
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cetuximab-responsive NRAS+/+ cells (Figure 2, bottom 
panels), further suggesting the central role of unresponsive 
ERK1/2 phosphorylation in the cetuximab-refractory 
phenotype of NRAS mutant cells.
NRAS-mutant cells are more resistant to MEK1/2 
inhibition
The phospho-proteomic signature of cetuximab-
sensitive NRAS+/+ cells strongly suggested that the anti-
proliferative mechanism of action of cetuximab in the 
SW48 model involved the deactivation of the MEK/
ERK transduction cascade downstream of EGFR. The 
refractoriness of NRASQ61K/+ cells to cetuximab, in turn, 
was consistent with the lack of inhibition of constitutively 
active MEK/ERK signaling in these cells. Given this, 
we examined the effects of four representative MEK1/2 
inhibitors [17-20], namely binimetinib (MEK162, 
ARRY-162, a MEK inhibitor developed by Array 
Biopharma), trametinib (GSK1120212, Mekinist, a MEK 
inhibitor developed by GlaxoSmithKline), selumetinib 
(AZD6244, a MEK inhibitor invented by Array and 
developed by AstraZeneca), and pimasertib (AS-703026, 
MSC1936369B, a MEK inhibitor developed by Merck 
KgaC) on cell viability of NRASQ61K/+ and NRAS+/+ cells. 
Scatter plots showing the interpolated IC50 values 
from dose-response curves revealed that NRASQ61K/+ cells 
were less responsive to MEK1/2 inhibitors than NRAS+/+ 
cells (Figure 3). Thus, although the decrease in cell 
viability was dose-dependent and complete within the 
range of concentrations of MEK1/2 inhibitors employed, 
and the IC50 values were < 1 µmol/L for most of the 
MEK1/2 inhibitors, we observed that the IC50 values 
significantly increased by 2- and 5-fold when using 
trametinib and selumetinib, respectively, in NRASQ61K/+ 
cells. The isogenic introduction of H1047R activating 
mutation at one of the endogenous PI3Kα loci, which is 
known to result in increased oncogenic PI3K pathway 
signaling, not only failed to alter the sensitivity to 
cetuximab (Figure 1) but also failed to promote resistance 
to MEK1/2 inhibitors in NRAS+/+ (Figure 3). Indeed, SW48 
PI3KαH1047R/+ cells exhibited a significantly increased 
sensitivity ( > 2-fold) to pimasertib and selumetinib when 
compared with SW48 PI3Kα+/+ parental cells.
Mutant NRAS activates a synthetic lethal 
interaction of MEK1/2 inhibitors combined with 
cetuximab
We next investigated the effects of combination 
treatment with MEK1/2 inhibitors and cetuximab. 
Whereas MEK1/2 inhibitors and cetuximab were highly 
effective as single agents in reducing cell viability in 
cetuximab-sensitive SW48 NRAS+/+ parental cells, 
as measured by the MTT reduction assay, concurrent 
exposure failed to show any synergistic effect. Thus, 
additive and less-than-additive (antagonistic) interactions 
occurred after combining graded concentrations of 
binimetinib, trametinib, selumetinib, and pimasertib 
with an optimal concentration of cetuximab (Figure 4, 
right panels), confirming that the combined treatment 
of MEK1/2 inhibitors with cetuximab could negatively 
interfere with cell growth inhibition in cetuximab-sensitive 
mCRC cells [21]. 
In cetuximab-refractory NRASQ61K/+ cells, however, 
the combined addition of any of the tested MEK1/2 
inhibitors together with cetuximab resulted in an increase 
in cell toxicity, which was significantly higher than the 
additive value of the 2 drugs alone. Interestingly, the 
synergistic interaction was particularly evident at lower 
inhibitory concentrations of MEK1/2 inhibitors, whereas 
little impact was observed at the higher levels of cell 
suppression (Figure 4, left panels). Accordingly, a very 
different picture emerged when MEK1/2 single-agent 
dose-response curves in cetuximab-untreated NRASQ61K/+ 
cells were compared with those when MEK1/2 inhibitors 
were combined with a largely ineffective concentration 
of cetuximab (eliciting < 20% inhibition of cell viability) 
(Figure 5). Co-exposure to cetuximab induced a 
conspicuous leftward shift in the dose-response curves of 
MEK1/2 inhibitors and, consequently, a manifest decrease 
in their IC50 values. Accordingly, 100 µg/mL cetuximab 
caused a 7-fold increase in NRASQ61K/+ binimetinib 
efficacy, an 11-fold increase in NRASQ61K/+ trametinib 
efficacy, a substantial 255-fold increase in NRASQ61K/+ 
selumetinib efficacy, and a remarkable > 1,300-fold 
increase in NRASQ61K/+ pimasertib efficacy. 
Cetuximab synergistically triggers apoptotic cell 
death with MEK1/2 inhibitors in NRAS mutant 
mCRC cells
To mechanistically explore the apparent synthetic 
lethal interaction between cetuximab and MEK1/2 
inhibition in NRAS-mutant mCRC cells, we investigated 
the possibility that the decrease in cell viability was the 
result of an increase in apoptosis. Thus, NRAS+/+ and 
NRASQ61K/+ cells were exposed to graded concentrations 
of the more efficient MEK1/2 inhibitors trametinib, 
selumetinib, and pimasertib for 72 h with or without 100 
µg/mL cetuximab, and mono- and oligo-nucleosomes 
released into the cytoplasm by apoptotic cells was 
measured by ELISA. The addition of MEK1/2 inhibitors 
as single agents had almost negligible effects on apoptosis 
of NRAS+/+ and NRASQ61K/+ cells. However, combination 
treatment of cetuximab with trametinib, selumetinib, 
or pimasertib resulted in enhanced apoptosis, which 
was significantly higher than the additive value of the 
2 drugs alone (Figure 6). Interestingly, this synergism 
occurred for NRASQ61K/+ cells and not for NRAS+/+ cells. 
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Figure 4: Cetuximab synergistically augments the toxicity of MEK1/2 against NRAS mutant mCRC cells. Cells seeded 
in 96-well plates (2,000-3,000 cells per well) were cultured in triplicate with or without graded concentrations of MEK1/2 plus/minus 
100 µg/mL cetuximab, which were not renewed during the entire period of cell exposure. For each pair of columns, the height of the left 
columns represents the sum of the toxic effect of each agent and, therefore, the expected toxicity if their effects were additive when used 
in combination. The total height of the right columns represents the observed toxicity when the agents were used in combination. The 
difference between the heights of the paired columns reflects the magnitude of antagonism or synergism on cell toxicity between MEK1/2 
inhibitors and cetuximab in NRAS+/+ (left panels) and NRASQ61K/+ (right panels) cells. Results are shown as mean (columns) ± SD (error 
bars) from at least three experiments in which triplicate wells were analyzed. 
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Figure 5: Cetuximab markedly sensitizes NRAS mutant mCRC cells to MEK1/2 inhibition. The cell viability effects from 
exposure of NRAS mutant cells to MEK1/2 inhibitors were analyzed by generating concentration-effect curves as a plot of the fraction of 
unaffected (surviving) cells versus drug concentration. Dose-response curves were plotted as percentages of the control cells’ absorbance ( 
= 100%), which was obtained from wells treated with appropriate concentrations of agent vehicles that were processed simultaneously. IC50 
values were designated for the concentrations of the agents decreasing absorbance values at 570 nm by 50%, as determined by interpolation 
using MTT-based colorimetric cell viability assays. Values are means ± SD from at least three experiments in which triplicate wells were 
analyzed. Sensitization factors were obtained by dividing IC50 values of MEK1/2 inhibitors alone by those obtained when cetuximab (100 
µg/mL) was simultaneously supplemented. 
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Accordingly, combination of pimasertib and cetuximab 
resulted in ~3-fold-increase in apoptotic cell death than 
with pimasertib alone, and a 3.5-fold increase than with 
cetuximab alone. These findings suggest that combination 
of cetuximab with MEK1/2 inhibitors results in extremely 
high, dose-dependent synthetic lethal effects executed, at 
least in part, by exacerbated apoptosis.
To investigate underlying pathways, we used a 
commercially available slide-based antibody array to 
simultaneously assess 18 intracellular signaling molecules 
Figure 6: Cetuximab augments MEK1/2 inhibitor-induced apoptotic cell death in NRAS mutant mCRC cells. 
Quantification of apoptosis-related cell death in NRAS+/+ (left panels) and NRASQ61K/+ (right panels) cells in response to 72 h treatment 
with graded concentrations of MEK1/2 inhibitors in the absence or presence of cetuximab (100 µg/mL), was determined as described in 
“Materials and methods”. Results are shown as mean (columns) ± SD (error bars) from at least three experiments in which duplicate wells 
were analyzed. 
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in their phosphorylated or cleaved state. When NRASQ61K/+ 
and NRAS+/+ cells were treated with graded concentrations 
of pimasertib, AKT phosphorylation at Ser473 was higher 
in NRAS+/+ cells than in NRASQ61K/+ cells (Figure 7). Co-
exposure to cetuximab failed to completely abrogate 
the strong activation of AKT induced by pimasertib in 
Figure 7: Cetuximab prevents AKT activation and promotes PARP cleavage in pimasertib-treated NRAS mutant 
mCRC cells. Left. Figure shows representative chemiluminiscent array images from the PathScan Intracellular Signaling array kit 
showing key phosphorylated signaling nodes in NRAS+/+ (left panels) and NRASQ61K/+ (right panels) treated with graded concentrations of 
pimasertib in the absence or presence of cetuximab. Right. Representative immunoblot analysis showing expression of phospho-ERK1/2 
and corresponding total-ERK1/2 after exposure to graded concentration of pimasertib in the absence or presence of cetuximab. 
Oncotarget82194www.impactjournals.com/oncotarget
NRAS+/+ parental cells. By contrast, addition of cetuximab 
was sufficient to prevent the weaker activation of AKT 
in pimasertib-treated NRASQ61K/+ cells, which was 
accompanied by the evident activation of intracellular 
mediators of apoptosis, such as cleaved PARP protein 
(Figure 7). The inverse correlation of AKT activation and 
PARP cleavage in response to pimasertib and cetuximab 
was paralleled by changes in the phosphorylation of 
MAPK; thus, whereas the concurrent treatment with 
cetuximab and pimasertib failed to further decrease the 
strong inactivation of ERK1/2 imposed by cetuximab in 
NRAS+/+ parental cells, the addition of cetuximab fully 
deactivated the remaining MAPK activity in pimasertib-
treated NRASQ61K/+ cells (Figure 7). 
Real-time monitoring of cell proliferation 
confirms the synergistic interaction between 
cetuximab and MEK1/2 inhibition in NRAS 
mutant mCRC cells
A limitation in the use of MTT reduction and cell 
death ELISA analysis is that because they are end-point 
assays, they offer only a snapshot of what is occurring. 
We therefore used an impedance-based RTCA platform to 
capture real-time kinetic data on cell growth after treatment 
with cetuximab and/or pimasertib. This technology 
generates a label-free environment for the cancer cells and 
can accurately inform about the characteristics of a cancer 
cell’s response to a treatment, without the use of toxic/end-
point assays leading to the termination of the experiment. 
Cell proliferation rates (Figure 8, top panel) and cell 
Figure 8: MEK1/2 inhibitor and cetuximab synergistically decrease the proliferation rate of NRAS mutant mCRC 
cells. The rate of proliferation was monitored in real-time using the xCELLligence system. Figure shows the rates of proliferation (top 
panel) and cell doubling times (bottom panel) in the presence of pimasertib (10 nmol/L), cetuximab (100 µg/mL), or pimasertib + cetuximab 
as determined by analyzing the growth curves shapes of NRAS+/+ (left panels) and NRASQ61K/+ between the 24 and 96 h hour interval. Results 
are shown as mean (columns) ± SD (error bars) from at least two experiments in which triplicate wells were analyzed.
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doubling times (Figure 8, bottom panel) for NRAS+/+ and 
NRASQ61K/+ cells cultured with or without pimasertib, 
cetuximab, or the combination pimasertib + cetuximab, 
were calculated as the slope of the growth curve of best 
fit from cell index recordings within a given time frame 
(i. e., between the 24 and 96 h interval). Cell proliferation 
in the presence of cetuximab was significantly higher in 
NRASQ61K/+ cells than in NRAS+/+ cells, thus confirming the 
refractoriness of NRASQ61K/+ cells to the anti-proliferative 
effects of cetuximab. Co-treatment with pimasertib and 
cetuximab markedly reduced the cell proliferation rate of 
NRASQ61K/+ cells, revealing a synergistic effect between 
MEK1/2 inhibition and cetuximab in NRASQ61K/+ cells but 
not in NRAS+/+ cells (Figure 8, top panel). Accordingly, 
a drastic > 70-fold increase in cell doubling time was 
observed in NRASQ61K/+ cell populations co-treated with 
the MEK1/2 inhibitor pimasertib and cetuximab (Figure 
8, bottom panel). 
DISCUSSION
Anti-EGFR monoclonal antibodies including 
cetuximab and panitumumab have improved the prognosis 
of a subgroup of patients with mCRC highly dependent 
on EGFR signaling. Retrospective studies based on 
prospectively randomized clinical trial data (prospective-
retrospective analysis) have confirmed that the best tool 
that oncologists have for selecting mCRC patients for anti-
EGFR antibody treatment is to exclude those with KRAS 
or NRAS mutations. Accordingly, international clinical 
guidelines recommend restricting the use of these drugs 
to mCRC patients with KRAS and NRAS wild-type tumors 
[24-26]. However, whereas RAS mutations represent the 
most important predictive biomarker of resistance to anti-
EGFR therapy in mCRC, and the only one approved for 
clinical use, there is an unmet need for new therapeutic 
strategies for RAS mutant tumors. Unfortunately, no 
therapy is available to specifically inhibit mutant RAS and 
current approaches mostly focus on inhibiting proteins 
of downstream signaling pathways. Our study leads us 
to propose that MEK1/2 inhibitors, in combination with 
cetuximab, might have clinical utility in NRAS-mutant 
mCRC patients. 
There are no known human colorectal cancer 
cell lines that express mutationally activated NRAS. 
To circumvent this problem, we exploited a recently 
developed cell culture system that accurately recapitulates 
the genetic changes present in human mCRC. We used an 
isogenic pair of mCRC cell lines in which homologous 
recombination has been used to knock-in Q61K, the most 
common driver mutation in NRAS. This experimental 
approach enables the identification of different outputs 
from wild-type and mutant NRAS without the confounding 
effects of significant differences in genetic background or 
the possibility of creating “artificial phenotypes” by forced 
overexpression of oncogenic forms. Thus, our study aimed 
to provide an unbiased global screen of signaling pathways 
downstream of endogenous oncogenic NRAS in response 
to the anti-EGFR monoclonal antibody cetuximab. 
Knock-in of the Q61K mutant allele rendered SW48 
cells, one of the most highly sensitive CRC cell lines to 
cetuximab treatment [21], fully refractory to the growth 
inhibitory activity of this antibody. Because SW48 cells 
should be viewed as a “quadruple wild-type” model for 
KRAS, BRAF, NRAS, and PIK3CA genes, these findings 
formally prove that a mono-allelic activating mutation of 
NRAS is sufficient to causally drive cetuximab resistance 
in EGFR-dependent mCRC cells. 
Despite the fact that mutant forms of RAS are 
thought to engage multiple downstream effectors to 
transmit their oncogenic signals, cetuximab-unresponsive 
ERK1/2 phosphorylation was the sole biomarker 
distinguishing cetuximab-refractory NRASQ61K/+ from 
cetuximab-sensitive NRAS+/+ cells in our assays. These 
results strongly suggest that NRAS-mutant mCRC cells 
exhibit intrinsic refractoriness to cetuximab by being 
able to efficiently channel signaling through the MEK/
ERK pathway. Our findings are in accord with an earlier 
landmark study showing that NRAS mainly signals 
through ERK to activate an anti-apoptotic phenotype, 
and suggesting that MEK1/2 inhibitors could be highly 
efficacious for patients with NRAS-mutant primary 
colorectal cancer [13]. But, it remained unclear in that 
study whether ERK1/2 activation was the particular 
effector pathway in NRAS mutant cells instrumental to 
mediate the cetuximab-resistant phenotype in mCRC. To 
explore this possibility, we used a panel of highly specific 
MEK inhibitors that have entered the laboratory and the 
clinic [17-20]. We noted, however, that pharmacological 
suppression of MEK1/2 activity failed to block the growth 
of cetuximab-resistant NRAS mutant cells. Although the 
finding that NRASQ61K/+ cells were significantly more 
resistant to pharmacological suppression of MEK1/2 was 
unexpected [12], we reasoned that ERK1/2 dependency 
associated with drugs inhibiting EGFR pathways, such 
as cetuximab, might become apparent only when the 
receptor itself was simultaneously targeted. Accordingly, 
concomitant blockade of EGFR with cetuximab and of 
MEK1/2 with pimasertib, a selective allosteric MEK 
inhibitor, was a highly effective combination to reduce 
the survival of NRASQ61K/+ cells. The synergistic pro-
apoptotic effect of MEK1/2 and EGFR inhibition imply 
that concurrent targeting of MEK and EGFR signaling 
may constitute a rational strategy for the treatment of 
NRAS mutant mCRC. 
While the lack of phosphorylated MAPK protein 
inhibition as a finding in primary resistance to cetuximab 
in NRAS-mutant mCRC cells concurs with earlier findings 
showing that primary and acquired resistance to EGFR 
inhibitors converge on the MAPK pathway [27, 28], the 
discovery that mCRC cells with resistance to cetuximab 
through an activating NRAS mutation display constitutive 
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activation of MEK, but are only modestly affected by 
MEK inhibitors, was intriguing. By surveying intracellular 
signaling pathways with pimasertib and cetuximab alone 
or in combination, we found that the intensity of adaptive 
responses engaging feedback loops (e.g., activation of the 
AKT pathway) might determine the success of tumoricidal 
responses in NRASQ61K/+ cells challenged with cetuximab. 
Although further investigations are needed to elucidate 
the precise biochemical mechanisms underlying the 
remarkably stronger effectiveness of the MEK-EGFR 
inhibitory combination in NRAS-mutant, but not in NRAS-
WT, mCRC cells [22, 23], it seems that AKT or ERK is 
activated as a counterpart signal when cells are exposed 
to MEK1/2 or EGFR inhibitors, respectively. Thus, 
whereas pimasertib inhibits the MEK/ERK pathway but 
induces an evident anti-apoptotic activation of AKT in 
NRAS+/+ cells, cetuximab does not inhibit the MEK/ERK 
pathway, but is able to abrogate the weaker activation of 
AKT in pimasertib-treated NRASQ61K/+ cells. Because the 
ability of AKT to promote survival is dependent on and 
proportional to its kinase activity, the inverse correlation 
between AKT activation and PARP cleavage might explain 
the exacerbated cell death response to pimasertib and 
cetuximab in NRASQ61K/+ but not in wild-type mCRC cells. 
Indeed, because real-time monitoring of cell proliferation 
confirmed that cetuximab co-treatment drastically 
augmented the growth inhibitory effects of pimasertib in 
NRAS mutant but not wild-type cells, it is reasonable to 
suggest that cetuximab might be a synthetic lethal agent 
[29, 30] in combination with MEK1/2 inhibitors for the 
NRAS mutant subgroup of mCRC. 
Overall, our results demonstrate that NRAS-
mutant mCRC cells display sustained activation of 
MEK/ERK that persists after cetuximab-induced 
EGFR blockade. Our report confirms the notion that, 
regardless of the gene/mutation that confers resistance 
to cetuximab (KRAS, BRAF, NRAS, MET, HER2), the 
net signaling output appears to invariably involve the 
constitutive phosphorylation of MEK/ERK. Although 
these data provide a rationale for overcoming primary 
NRAS mutation-driven primary (de novo) and secondary 
(acquired) resistance to cetuximab using MEK inhibitors, 
we found that pharmacological inhibition of MEK1/2 
alone failed to more efficiently impair the growth of 
cetuximab-refractory NRAS-mutant cells. Circumvention 
of cetuximab refractoriness in NRAS mutant mCRC cells 
seems to be dependent on the concomitant blockade of 
MEK and EGFR, and this was required to fully curb 
the proliferation and survival of cetuximab-refractory 
NRAS-mutant cells. Whereas individual agents produced 
little or no induction of apoptosis, concomitant blockade 
of MEK1/2 and EGFR severely impaired the growth of 
NRAS-mutant cells by promoting high levels of apoptotic 
cell death, thus corroborating that a double hit (MEK-
EGFR) is required to achieve a more effective inhibition 
of key intracellular signals and compensatory feedbacks 
for cell survival and proliferation in NRAS-mutant mCRC 
cell populations. 
mCRC patients with a mutant NRAS gene are in 
dire need of better treatment options. Our study provides 
pre-clinical evidence for promising synergies between the 
EGFR antagonist cetuximab and drugs targeting MEK1/2 
in NRAS mutant mCRC. The synthetic lethality approach 
may be particularly valuable for the treatment of mCRC 
with “undruggable” oncogenic drivers such as NRAS, a 




The X-MAN™ isogenic cell lines SW48 NRAS-
WT PI3Kα-WT (NRAS+/+ PI3Kα+/+), SW48 NRASQ61K/+ 
(Cat# HD 103-017), and SW48 PI3KαH1047R/+ (Cat# HD 
103-005), were purchased from Horizon Discovery 
Ltd. (Cambridge, UK) and maintained according to the 
supplier´s recommendations in RPMI 1640 with 2 mmol/L 
L-glutamine, 25 mmol/L sodium bicarbonate and 10% 
FBS. 
Drugs and materials
Cetuximab was kindly provided by the Hospital 
Universitari de Girona Dr. Josep Trueta Pharmacy (Girona, 
Spain). Cetuximab was solubilized using 10 mmol /L 
NaCl in phosphate buffered saline (PBS) at pH 7.2 in 
bacteriostatic water for injection purposes (stock solution 
was 2 mg/mL), stored at 4 °C and used within 1 month of 
preparation. MEK1/2 inhibitors binimetinib, trametinib, 
selumetinib, and pimasertib were purchased from Selleck 
chemicals Inc. (Houston, TX). MEK1/2 inhibitors were 
dissolved in sterile dimethylsulfoxide (DMSO) and a 10 
mmol/l stock solution was prepared and stored in aliquots 
at -20 oC. Working concentrations were diluted in culture 
medium prior each experiment. ERK1/2 and phospho-
ERK1/2 rabbit polyclonal antibodies were from Cell 
Signaling Technology (Beverly, MA).
Metabolic status assessment (MTT-based cell 
viability assays)
Cell viability was determined using a standard 
colorimetric MTT (3-4,5-dimethylthiazol-2-yl-2,5-
diphenyl-tetrazolium bromide) reduction assay. For each 
treatment, cell viability was evaluated as a percentage 
using the following equation: (OD570 of the treated sample/
OD570 of the untreated sample)×100.
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Phospho-proteome profiling
Cells were rinsed with cold-PBS and immediately 
solubilized in NP-40 lysis buffer (1% NP-40, 20 mmol/L 
Tris-HCl (pH 8.0), 137 mmol /L NaCl, 10% glycerol, 
2 mmol/L  EDTA, 1 mmol/L  sodium orthovanadate, 10 μg/
mL aprotinin and 10 μg/mL leupeptin) by rocking the 
lysates gently at 4 °C for 30 min. Following centrifugation 
at 14 000 × g for 5 min, supernatants were transferred to a 
clean test tube and protein concentrations were determined 
using the BCA Protein kit (Pierce, Rockford, IL). Lysates 
were diluted and incubated with Human Phospho-MAPK 
and Human Phospho-Kinase (Proteome Profiler; R&D 
Systems; Minneapolis, MN) as per the manufacturer’s 
instructions. In this method, capture and control antibodies 
were spotted in duplicate on nitrocellulose membranes. 
Briefly, the membranes were blocked with 5% bovine 
serum album (BSA) in TBS (0.01 mol/L Tris-HCl, pH 7.6) 
for 1 h. Membranes were then incubated with 750 μg of 
total protein. After extensive washing with TBS including 
0.1% v/v Tween-20, three times for 5 min, to remove 
unbound materials, membranes were incubated with 
HRP-conjugated secondary antibodies for 2 h at room 
temperature (RT). Unbound HRP antibody was washed 
out with TBS/ 0.1% v/v Tween-20. Finally, array data 
were developed on X-ray film using a chemiluminescence 
detection system (Amersham Life Sciences, Piscataway, 
NJ). Densitometry analyses of the scanned phospho-arrays 
were carried out using Carestream Molecular Imaging 
Software. 
Apoptosis assay
Apoptosis was assessed using the Cell Death 
Detection ELISAPLUS Kit from Roche Diagnostics 
(Barcelona, Spain). Briefly, cells (5-10 × 103 cells per well) 
were grown in 96-well plates and treated in triplicate with 
the indicated doses of MEK1/2 inhibitors, cetuximab, or 
MEK1/2 inhibitors + cetuximab for 72 h. Pelleted cells 
were treated with lysis buffer for 30 min at RT. Anti-
histone biotin and anti-DNA peroxidase antibodies were 
then added to each well followed by incubation at RT 
for 2 h. After three washes, the peroxidase substrate was 
added to each well, and the plates were read at 405 nm 
at multiple time intervals. The enrichment of histone-
DNA fragments in treated cells was expressed as the fold 
increase in absorbance relative to control (vehicle-treated) 
cells using the following formula: [A405−A490]TREATED/ [A405−
A490]UNTREATED.
PathScan sandwich immunoassay
The PathScan® Intracellular Signaling array kit 
(Cell Signaling Technology, #7323) was used. Briefly, 
overnight serum-starved cells cultured in the presence of 
graded concentrations of pimasertib with or without 100 
µg/mL cetuximab were washed with ice-cold 1× PBS and 
lysed in 1× Cell Lysis buffer. The Array Blocking Buffer 
was added to each well followed by incubation for 15 min 
at RT. Subsequently, the lysate was added to each well 
and incubated for 2 h at RT. After washing, the detection 
antibody cocktail was added to each well and incubated 
for 1 h at RT. Horseradish peroxidase (HRP)-linked 
streptavidin was added to each well and incubated for 30 
min at RT. The slide was then covered with ECL Clarity 
(Bio-Rad) and images were captured.
Immunoblotting
Cells were washed two times with PBS and then 
lysed in buffer [20 mmol/L Tris (pH 7.5), 150 mmol/L 
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton 
X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L 
β-glycerolphosphate, 1 mmol/L Na3VO4, 1 µg/mL 
leupeptin, 1 mmol/L phenylmethylsulfonylfluoride] for 30 
min on ice. The lysates were cleared by centrifugation (15 
min at 14.000 rpm, 4 oC). Protein content was determined 
against a standardized control using the Pierce protein 
assay kit (Rockford, IL). Equal amounts of protein (50 
µg) were heated in SDS sample buffer (Laemmli) for 10 
min at 70 oC, subjected to electrophoresis on 10% SDS-
PAGE, and transferred to nitrocellulose membranes. 
Nonspecific binding on the nitrocellulose filter was 
minimized by blocking for 1 h at room temperature (RT) 
with TBS-T [25 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 
7.5), and 0.05% Tween 20] containing 5% (w/v) nonfat 
dry milk. The treated filters were washed in TBS-T and 
then incubated overnight at 4 oC with primary antibody in 
TBS-T/5% bovine serum albumin (BSA). The membranes 
were washed in TBS-T, horseradish peroxidase-conjugated 
secondary antibodies (Jackson Immuno Research, West 
Grove, PA) in TBS- containing 5% (w/v) nonfat dry milk 
were added for 1 h, and immunoreactive bands were 
visualized with the Clarity™ Western ECL Substrate (Bio-
Rad). 
Real-time cell growth rates
Proliferation was measured by using the 
xCELLigence RTCA DP Instrument (ACEA Biosciences, 
San Diego). Cells were plated at 20,000 cells/well in fresh 
medium in 200 µL in an E-plate 16. Initial attachment and 
growth were continuously monitored for approximately 
24 h at 37 oC and 5% CO2 for stabilization. Then, 100 
µL of medium was removed from each well and replaced 
with fresh medium with or with compounds to achieve 
the appropriate final concentrations. The plate remained 
in the RTCA Station for 96 h and cell proliferation was 
monitored in real time and plotted using RTCA software. 
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Three biological replicates were evaluated in each 
experiment. Cellular growth rate was determined by 
the slope of the growth curve using the RTCA Software 
Package 1.2, which permits normalization to any time 
point, and results can be directly viewed in the software 
window. We conducted the normalization at one time point 
before the treatment. 
Statistical analysis
All observations were confirmed by at least 
three independent experiments. Data are presented as 
mean ± SD. Two-group comparisons were performed 
using Student´s t test for paired and unpaired values. 
Comparisons of means of ≥ 3 groups were performed by 
ANOVA, and the existence of individual differences, in 
case of significant F values at ANOVA, tested by Scheffé’s 
multiple contrasts. P values < 0.01 were considered to be 
statistically significant (denoted as*). All statistical tests 
were two-sided. 
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